First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of ...
Greetings, and welcome to the ALX Oncology Third Quarter 2025 Financial Results Conference Call and Webcast. [Operator Instructions] Please note, this conference is being recorded. I would now like to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback